Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
Open Access
- 1 June 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (11) , 846-853
- https://doi.org/10.1093/jnci/dji144
Abstract
Background: Ursodeoxycholic acid (UDCA) treatment is associated with a reduced incidence of colonic neoplasia in preclinical models and in patients with conditions associated with an increased risk for colon cancer. We conducted a phase III, double-blind placebo-controlled trial of UDCA to evaluate its ability to prevent colorectal adenoma recurrence. Methods: We randomly assigned 1285 individuals who had undergone removal of a colorectal adenoma within the past 6 months to daily treatment with UDCA (8–10 mg/kg of body weight; 661 participants) or with placebo (624 participants) for 3 years or until follow-up colonoscopy. Recurrence rates (number of recurrent adenomas per unit time) were compared by use of a Huber–White variance estimator. Proportions of participants with one or more recurrent adenomas were compared with a Pearson chi-square statistic; adjusted odds ratios (ORs) were obtained by logistic regression. All statistical tests were two-sided. Results: We observed a non–statistically significant 12% reduction in the adenoma recurrence rate associated with UDCA treatment, compared with placebo treatment. However, UDCA treatment was associated with a statistically significant reduction ( P = .03) in the recurrence of adenomas with high-grade dysplasia (adjusted OR = 0.61, 95% confidence interval = 0.39 to 0.96). We observed no statistically significant differences between UDCA and placebo groups in recurrence with regard to adenoma size, villous histology, or location. Conclusions: UDCA treatment was associated with a non–statistically significant reduction in total colorectal adenoma recurrence but with a statistically significant 39% reduction in recurrence of adenomas with high-grade dysplasia. Because severely dysplastic lesions have a high risk of progression to invasive colorectal carcinoma, this finding indicates that future chemoprevention trials of UDCA in individuals with such lesions should be considered.Keywords
This publication has 33 references indexed in Scilit:
- Ursodeoxycholic Acid Therapy and the Risk of Colorectal Adenoma in Patients With Primary Biliary Cirrhosis: An Observational StudyHepatology, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- Bile Acids Reduce the Apoptosis-Inducing Effects of Sodium Butyrate on Human Colon Adenoma (AA/C1) Cells: Implications for Colon CarcinogenesisBiochemical and Biophysical Research Communications, 2000
- The stress-response proteins poly(ADP-ribose) polymerase and NF-κB protect against bile salt-induced apoptosisCell Death & Differentiation, 1998
- Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferationNutrition and Cancer, 1998
- Primary chemoprevention strategies for colorectal cancer: Ursodeoxycholic acid and other agentsGastroenterology, 1995
- Selective preservation of protein kinase C‐ζ in the chemoprevention of azoxymethane‐induced colonic tumors by piroxicamFEBS Letters, 1995
- Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in ratsDiseases of the Colon & Rectum, 1989
- Relationship between duodenal bile acids and colorectal neoplasia.Gut, 1987
- Stimulation of deoxythymidine incorporation in the colon of rats treated intrarectally with bile acids and fatsCarcinogenesis: Integrative Cancer Research, 1983